3-(5-甲基异恶唑-3-基)吡啶 | 85903-32-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 中文名称: 3-(5-甲基异恶唑-3-基)吡啶
• 英文名称: 5-methyl-3-(3-pyridyl)isoxazole
• 英文别名: 3-(5-methyl-isoxazol-3-yl)-pyridine；5-Methyl-3-(3-pyridyl)isoxazol；5-Methyl-3-(pyridin-3-yl)isoxazole；5-methyl-3-pyridin-3-yl-1,2-oxazole
• CAS: 85903-32-8
• 化学式: C₉H₈N₂O
• 分子量: 160.175
• InChiKey: VVVHOKHVHXUUEN-UHFFFAOYSA-N

物化性质

• 熔点：
  71-72 °C (sublm)
• 沸点：
  309.6±27.0 °C(Predicted)
• 密度：
  1.142±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.11
• 拓扑面积：
  38.9
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  3-[chloro(hydroximino)methyl]pyridinium chloride 、 丙炔 在 三乙胺 作用下， 以 乙醇 为溶剂， 以41.4%的产率得到3-(5-甲基异恶唑-3-基)吡啶
  参考文献：
  名称：

  3-Pyridylisoxazoles as prototypes of antiaggregatory agents

  摘要：

  合成了一系列5-烷基-3-吡啶基异噁唑化合物，采用3-(3-吡啶基)异噁唑作为骨架。该系列所有化合物在浓度范围6•10–6–6•10–4 mol L–1内均表现出抗聚集活性。对抗聚集活性的实验数据分析表明，异噁唑环中5位烷基取代基存在空间限制。5-烷基-3-(3-吡啶基)异噁唑对血小板膜受体具有较为明显的选择性。

  DOI：

  10.1007/s11172-018-2151-2

文献信息

• NOVEL HETEROCYCLIC COMPOUNDS AS PESTICIDES
  申请人：Bretschneider Thomas

  公开号：US20130261141A1

  公开（公告）日：2013-10-03

  The present application relates to novel heterocyclic compounds, to processes for preparation thereof and to the use thereof for controlling animal pests, which also include arthropods and especially insects.

  本申请涉及新颖的杂环化合物，其制备方法以及用于控制动物害虫的用途，其中包括节肢动物，特别是昆虫。
• 6,11-BICYCLOLIDES: BRIDGED BIARYL MACROLIDE DERIVATIVES
  申请人：KIM IN JONG

  公开号：US20090075915A1

  公开（公告）日：2009-03-19

  The present invention discloses compounds of formula I, or pharmaceutically acceptable salts, esters, or prodrugs thereof: which exhibit antibacterial properties. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject in need of antibiotic treatment. The invention also relates to methods of treating a bacterial infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The invention further includes process by which to make the compounds of the present invention.

  本发明揭示了以下化合物的化学式I，或其药学上可接受的盐、酯或前药：这些化合物具有抗菌性能。本发明还涉及包含上述化合物的药物组合物，用于治疗需要抗生素治疗的患者。该发明还涉及通过给予含有本发明化合物的药物组合物来治疗患者的细菌感染的方法。该发明还包括制备本发明化合物的方法。
• SPIRO-OXINDOLE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS
  申请人：Chafeev Mikhail

  公开号：US20100137299A1

  公开（公告）日：2010-06-03

  This invention is directed to spiro-oxindole compounds, as stereoisomers, enantiomers, tautomers thereof or mixtures thereof; or pharmaceutically acceptable salts, solvates or prodrugs thereof, for the treatment and/or prevention of sodium channel-mediated diseases or conditions, such as pain.

  本发明涉及螺环氧吲哚化合物，包括其立体异构体、对映异构体、互变异构体或其混合物；或其药学上可接受的盐、溶剂化合物或前药，用于治疗和/或预防钠通道介导的疾病或症状，例如疼痛。
• SPIRO-OXINDOLE COMPOUNDS AND THEIR USES AS THERAPEUTIC AGENTS
  申请人：Chafeev Mikhail

  公开号：US20120295897A1

  公开（公告）日：2012-11-22

  This invention is directed to spiro-oxindole compounds, as stereoisomers, enantiomers, tautomers thereof or mixtures thereof; or pharmaceutically acceptable salts, solvates or prodrugs thereof, for the treatment and/or prevention of sodium channel-mediated diseases or conditions, such as pain.

  本发明涉及螺环氧吲哚化合物，包括立体异构体、对映体、互变异构体或其混合物；或其药学上可接受的盐、溶剂合物或前药，用于治疗和/或预防钠通道介导的疾病或病症，例如疼痛。
• BELGODERE, E.;BOSSIO, R.;SIO, F.;MARCACCINI, S.;PEPINO, R., HETEROCYCLES, 1983, 20, N 3, 501-504
  作者：BELGODERE, E.、BOSSIO, R.、SIO, F.、MARCACCINI, S.、PEPINO, R.

  DOI：——

  日期：——